Direct oral anticoagulants versus warfarin for the treatment of inferior vena cava thrombus
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
OBJECTIVE: To evaluate the efficacy and safety of direct oral anticoagulants (DOACs) compared to warfarin in patients with inferior vena cava (IVC) thrombus.
METHODS: This was a single-system, retrospective cohort study of hospitalized adult patients with IVC thrombus treated with a DOAC or warfarin therapy. The primary efficacy endpoint was the thrombus resolution on imaging, and the primary safety endpoint was major bleeding, both assessed within 6 months of hospital discharge. Secondary endpoints included hospitalization for a bleeding-related event, pulmonary embolism, or death within 6 months of hospital discharge.
RESULTS: A total of 33 patients were included in the study. Twenty-three (70%) patients received a DOAC, and 10 (30%) received warfarin. Of the 10 patients with repeat imaging available, complete resolution was noted in two (33%) DOAC patients and no warfarin patients (p = .5). Major bleeding occurred in two (8.7%) DOAC patients and one (10%) warfarin patient (p = .9). No significant differences in secondary endpoints were observed between groups.
CONCLUSIONS: There were no differences in efficacy and safety between patients receiving DOACs or warfarin for the treatment of IVC thrombus, although results are limited by the small patient population and number of patients with repeat imaging available.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:111 |
|---|---|
| Enthalten in: |
European journal of haematology - 111(2023), 6 vom: 08. Dez., Seite 909-913 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mihm, Alexandra E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5Q7ZVV76EI |
|---|
| Anmerkungen: |
Date Completed 09.11.2023 Date Revised 09.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ejh.14097 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361857802 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361857802 | ||
| 003 | DE-627 | ||
| 005 | 20231226090032.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ejh.14097 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1206.xml |
| 035 | |a (DE-627)NLM361857802 | ||
| 035 | |a (NLM)37688288 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mihm, Alexandra E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Direct oral anticoagulants versus warfarin for the treatment of inferior vena cava thrombus |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.11.2023 | ||
| 500 | |a Date Revised 09.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a OBJECTIVE: To evaluate the efficacy and safety of direct oral anticoagulants (DOACs) compared to warfarin in patients with inferior vena cava (IVC) thrombus | ||
| 520 | |a METHODS: This was a single-system, retrospective cohort study of hospitalized adult patients with IVC thrombus treated with a DOAC or warfarin therapy. The primary efficacy endpoint was the thrombus resolution on imaging, and the primary safety endpoint was major bleeding, both assessed within 6 months of hospital discharge. Secondary endpoints included hospitalization for a bleeding-related event, pulmonary embolism, or death within 6 months of hospital discharge | ||
| 520 | |a RESULTS: A total of 33 patients were included in the study. Twenty-three (70%) patients received a DOAC, and 10 (30%) received warfarin. Of the 10 patients with repeat imaging available, complete resolution was noted in two (33%) DOAC patients and no warfarin patients (p = .5). Major bleeding occurred in two (8.7%) DOAC patients and one (10%) warfarin patient (p = .9). No significant differences in secondary endpoints were observed between groups | ||
| 520 | |a CONCLUSIONS: There were no differences in efficacy and safety between patients receiving DOACs or warfarin for the treatment of IVC thrombus, although results are limited by the small patient population and number of patients with repeat imaging available | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a direct oral anticoagulant | |
| 650 | 4 | |a inferior vena cava thrombus | |
| 650 | 4 | |a vitamin K antagonist | |
| 650 | 4 | |a warfarin | |
| 650 | 7 | |a Warfarin |2 NLM | |
| 650 | 7 | |a 5Q7ZVV76EI |2 NLM | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 700 | 1 | |a Bacchus, Arefa |e verfasserin |4 aut | |
| 700 | 1 | |a Harb, Kathleen J |e verfasserin |4 aut | |
| 700 | 1 | |a Menear, Richard A |e verfasserin |4 aut | |
| 700 | 1 | |a Nisly, Sarah A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of haematology |d 1990 |g 111(2023), 6 vom: 08. Dez., Seite 909-913 |w (DE-627)NLM01261727X |x 1600-0609 |7 nnns |
| 773 | 1 | 8 | |g volume:111 |g year:2023 |g number:6 |g day:08 |g month:12 |g pages:909-913 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ejh.14097 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 111 |j 2023 |e 6 |b 08 |c 12 |h 909-913 | ||